Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): Current updates

Henu Kumar Verma, Batoul Farran, Lakkakula V.K.S. Bhaskar

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

While there is no proven treatment available for coronavirus disease 2019 (COVID-19), convalescent plasma (CP) may provide therapeutic relief as the number of cases escalate steeply world-wide. At the time of writing this review, vaccines, monoclonal antibodies or drugs are still lacking for the recent large COVID-19 outbreak, which restores the interest in CP as an empirical life-saving treatment. However, formal proof of efficacy is needed. The purpose of this review is to summarize all historical clinical trials on COVID-19 infected patients treated with CP to provide precise evidence for the efficacy and effectiveness of CP therapy in severe COVID- 19 patients. Although there are many clinical trials in progress, high-quality clinical evidence is still lacking to analyze the existing problems. Meanwhile, based on the previous successful outcomes, we recommend healthcare systems to use CP therapy cautiously in critically ill COVID-19 patients.

Original languageEnglish (US)
Pages (from-to)115-125
Number of pages11
JournalAntibody Therapeutics
Volume3
Issue number2
DOIs
StatePublished - 2020
Externally publishedYes

Keywords

  • Clinical trials
  • Convalescent plasma
  • Corona virus
  • COVID-19
  • Pathogen inactivation
  • Serology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): Current updates'. Together they form a unique fingerprint.

Cite this